Starfish Neuroscience

Starfish Neuroscience operates at the intersection of neuroscience, medical devices, and brain-computer interfaces. Its stated focus is brain interfaces for neurological and neuropsychiatric conditions, with products spanning non-invasive TMS and implantable neural recording and stimulation. That breadth gives the company a different product mix from competitors often discussed in the same brain-interface conversation. Starfish’s stated differentiators are its minimally invasive approach, wireless and battery-free implant design, and ability to record and stimulate across multiple brain regions; these are design aims, not evidence of clinical performance or regulatory clearance. The company is categorized across biotechnology, medical, health care, life science, and neuroscience. Its reported team size is in the 1–10 employee band, placing it at an early, small-team stage relative to more established players.

The available indicators point to an early-stage company moving from research and engineering toward product development, but do not establish commercial traction. The clearest development milestone came in May 2025, when the company announced a custom neural chip intended for a wireless, battery-free brain implant and described collaboration with imec. The announcement targeted late 2025 for release. The listed portfolio—TMS, distributed neural implants, thermal modulation, and a custom electrophysiology chip—suggests work across several device concepts, although no launch dates, clinical milestones, or revenue data are provided for most of them.